WASHINGTON, Aug. 12 -- National Institutes of Health has issued a notice called: Government Owned Invention Available for License: Monoclonal Antibody (RO4) That Reacts With the Juxta-Membrane Region of Mesothelin.
The notice was published in the Federal Register on Aug. 12 by Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute.
Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a novel monoclonal antibody (mAb), RO4, that can be used to treat mesothelin (MSLN) expressing cancers.
For more information, contact Inquiries related to this license opportunity should be directed to: Laurie Whitney, Ph.D, Unit Supervisor, NCI, Technology Transfer ...